| New insights on thrombolytic treatment of acute ischemic stroke. | |
| | |
MedLine Citation:
|
PMID: 11898496 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In 1995, a two-part randomized trial showed the efficacy of intravenous tissue plasminogen activator (tPA) when given within 3 hours of onset of symptoms of acute ischemic stroke. Two subsequent trials were unable to extend the therapeutic window of intravenous tPA beyond 3 hours. A phase IV study performed by experienced stroke centers showed an acceptably low symptomatic intracerebral hemorrhage rate for intravenous tPA of only 3%, whereas a review of the Cleveland area experience showed a disturbingly high rate of symptomatic intracerebral hemorrhage of 15.7%. The Prolyse in Acute Cerebral Thromboembolism (PROACT) II study showed efficacy of intra-arterial pro-urokinase and intravenous heparin over intravenous heparin alone when given within 6 hours of onset of symptoms to patients with thrombotic occlusion of the proximal middle cerebral artery. Additional controlled investigations of intra-arterial thrombolytic therapy are needed. Neuroprotectants in combination with intravenous tPA have yet to show improved efficacy over the use of tPA alone. |
| | |
Authors:
|
J F Meschia; T G Brott |
Related Documents
:
|
10762516 - Intra-arterial thrombolysis for the treatment of perioperative childhood cardioembolic ... 15197536 - Dilatation induced by 5-ht in the middle meningeal artery of the anaesthetised cat. 3631116 - Role of thrombolysis in peripheral arterial occlusion. 11455286 - An unusual source of massive intra-abdominal hemorrhage during cardio-pulmonary bypass. 14646676 - Addition of cytochalasin d to a biocompatible oil stent coating inhibits intimal hyperp... 7331866 - Complications of coronary angiography. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current neurology and neuroscience reports Volume: 1 ISSN: 1528-4042 ISO Abbreviation: Curr Neurol Neurosci Rep Publication Date: 2001 Jan |
Date Detail:
|
Created Date: 2002-03-18 Completed Date: 2002-04-08 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100931790 Medline TA: Curr Neurol Neurosci Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 19-25 Citation Subset: IM |
Affiliation:
|
Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. meschia.james@mayo.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Animals Brain Ischemia / complications, surgery, therapy* Fibrinolytic Agents / therapeutic use Humans Neuroprotective Agents / therapeutic use Streptokinase / therapeutic use Stroke / etiology, surgery, therapy* Thrombolytic Therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; 0/Neuroprotective Agents; EC 3.4.-/Streptokinase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Current status of neuroprotective agents in the treatment of acute ischemic stroke.
Next Document: The role of neuroimaging in selecting treatments for patients with acute stroke.